Company: ZVRA
Filing Date: 2025-03-31
Form Type: PREC14A
Source: 0001193125-25-068746
Chunk: 69

Company: ZEVRA THERAPEUTICS, INC.
Filing Date: 2025-03-31
Form: PREC14A
Chunk 69
---
     |               - |
| Total Adjustments                                                                                                                                                                                         |     |  $1,968,090 |     |       -$144,914 |

67

Relationship Between Financial Performance Measures The graphs below compare the compensation actually paid to our PEOs and the average of the compensation actually paid to our remaining named executive officers, with (i) our cumulative TSR, and (ii) our net income, in each case, for the fiscal years ended December 31, 2024, 2023 and 2022. TSR amounts reported in the graph assume an initial fixed investment of $100. 68

Our Compensation Committee has adopted a non-employeedirector compensation policy (the Ninth Amended and Restated Non-Employee Director Compensation Policy), which provides for cash stipends to be paid to each of our non-employeedirectors for service on the Board and for service on the Audit Committee, the Compensation Committee and the Nominating and Corporate Governance Committee. These stipends are payable in four equal quarterly installments on the last day of each quarter. The cash stipends payable under this policy were as follows for 2024:

|                                                 |     |   Member Annual 
 Service Stipend |     | Chairman Annual Service Stipend |
| Board of Directors                              |     |         $40,000 |     |                        $115,000 |
| Audit Committee                                 |     |          $9,000 |     |                         $22,500 |
| Compensation Committee                          |     |          $7,000 |     |                         $15,000 |
| Nominating and Corporate Governance Committee   |     |          $5,000 |     |                         $12,500 |
| Lead independent director (if one is appointed) |     |         $15,000 |     |                               - |

Additionally, under this policy, each non-employeedirector who continues to serve as a non-employeemember of our Board, following the annual meeting of our stockholders is eligible to receive an option to purchase 39,200 shares (or, for the Chairman of the Board, 49,200 shares) of our common stock at an exercise price equal to the last reported sale price of our common stock on The Nasdaq Stock Market on the date of grant. These stock options will vest and become exercisable in full on the earliest of (i) the first anniversary of the grant date, (ii) the day before the first annual stockholders meeting occurring after the grant date or (iii)